CD274 and Merkel cell skin cancer: Thus, the advent of immunotherapy, particularly ICI targeting the PD-1/PD-L1 axis (e.g., pembrolizumab and avelumab), has transformed the treatment landscape for advanced-stage MCC [31,32].